Should Stereotactic Ablative Radiotherapy Be Used for Oligometastatic Disease?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319839.
- Also identified by DOI 10.1056/EVIDtt2200209.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Should SABR Be Used for Oligometastatic Disease?The efficacy of stereotactic ablative radiotherapy in the oligometastatic setting has not been shown in phase 3 randomized controlled trials for breast (or many other) cancers. We review the evidence base and propose a trial to address the question, should stereotactic ablative radiotherapy be used for oligometastatic disease?
Medical subject headings
- Neoplasms
- Radiosurgery